Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05205447 · ClinicalTrials.gov registry record · Phase 1
Study of the Effects of Itraconazole and Carbamazepine on LY3410738 in Healthy Participants
A Phase 1 study, sponsored by Eli Lilly and Company.
- Terminated
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
NCT05205447 is a Phase 1 study that was terminated before completion, run by Eli Lilly and Company. The registered enrollment target is 27 participants.
The verdict
NCT05205447, a Phase 1 study, was terminated before completion, sponsored by Eli Lilly and Company.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
Study Summary
The main purpose of this study is to learn about how itraconazole and carbamazepine affect the levels of LY3410738 in the blood stream of healthy participants. Participation could last up to 75 days.
Interventions
- DRUG Itraconazole
- DRUG Carbamazepine
- DRUG LY3410738
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2022-01-05 |
| Est. Completion | 2022-04-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05205447
The ClinicalTrials.gov registry entry for NCT05205447 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Itraconazole is the first listed.
NCT05205447 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05205447 about?
NCT05205447 is a clinical study titled "Study of the Effects of Itraconazole and Carbamazepine on LY3410738 in Healthy Participants". The main purpose of this study is to learn about how itraconazole and carbamazepine affect the levels of LY3410738 in the blood stream of healthy participants. Participation could last up to 75 days.
What is the current status of trial NCT05205447?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2022-01-05. Estimated completion is 2022-04-12.
What interventions are being tested in trial NCT05205447?
The interventions under investigation include: Itraconazole (DRUG), Carbamazepine (DRUG), LY3410738 (DRUG).
Who is sponsoring clinical trial NCT05205447?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.